Advancements of Clinical and Basic Research in Oral Submucous Fibrosis

doi:10.13701/j.cnki.kqyxyj.2022.08.001

Abstract

Abstract: Oral submucosal fibrosis (OSF) is a collagen deposition disease characterized by scarring and tissue fibrosis, which can severely affect the oral function and quality of life of patients. According to the World Health Organization (WHO), there are more than 5 million OSF patients worldwide, with malignant transformation rates ranging from 1.5%-15%. Thus WHO has included it in the category of potentially malignant disorders of the oral cavity. The clinical and basic research progress of OSF is reviewed in this paper, with aim to provide a reference for understanding the pathogenesis of the disease and its early clinical prevention and treatment.

Key words: oral submucosal fibrosis, diagnosis, treatment

TANG Zhangui, CHENG Yuxi. Advancements of Clinical and Basic Research in Oral Submucous Fibrosis[J]. Journal of Oral Science Research, 2022, 38(8): 705-709.

References

[1] Liu B, Shen M, Xiong J, et al. Synergistic effects of betel quid chewing, tobacco use (in the form of cigarette smoking), and alcohol consumption on the risk of malignant transformation of oral submucous fibrosis (OSF): a case-control study in Hunan Province, China [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 120(3):337-345.
[2] Yadav A, Kumar L, Misra N, et al. Estimation of serum zinc, copper, and iron in the patients of oral submucous fibrosis [J]. Natl J Maxillofac Surg, 2015, 6(2):190-193.
[3] Abidullah M, Gaddikeri K, Anjum B, et al. Evaluation of hematological profile in oral submucous fibrosis [J]. Cureus, 2022, 14(2):e21926.
[4] Choudhury Y, Sharan RN. Altered BRCA1 and BRCA2 responses and mutation of BRCA1 gene in mice exposed chronically and transgenerationally to aqueous extract of betel nut (AEBN) [J]. Environ Toxicol Pharmacol, 2011, 31(1):57-69.
[5] Moutasim KA, Jenei V, Sapienza K, et al. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis [J]. J Pathol, 2011, 223(3):366-377.
[6] Ayinampudi BK, Narsimhan M. Salivary copper and zinc levels in oral pre-malignant and malignant lesions [J]. J Oral Maxillofac Pathol, 2012, 16(2):178-182.
[7] Jayasooriya PR, Nadeeka Jayasinghe KA, Mudiyanselage Tilakaratne W. Relationship between thickness of fibrosis and epithelial dysplasia in oral submucous fibrosis [J]. J Investig Clin Dent, 2011, 2(3): 171-175.
[8] Ho YC, Yang SF, Lee SS, et al. Regulation of hypoxia-inducible factor-1α in human buccal mucosal fibroblasts stimulated with arecoline [J]. J Formos Med Assoc, 2017,116(6): 484-487.
[9] Chakraborti S, Paul RR, Pal M, et al. Collagen deposition correlates with loss of E-cadherin and increased p63 expression in dysplastic conditions of oral submucous fibrosis [J]. Med Mol Morphol, 2022, 55(1):20-26.
[10] Nag R, Paul RR, Pal M, et al. Epithelial distribution of E-cadherin, p63, and mitotic figures in apotome images to determine the oncogenic potentiality of oral submucous fibrosis [J]. Microsc Microanal, 2020, 26(6):1198-1210.
[11] Desai RS, Mamatha GS, Khatri MJ, et al. Immunohistochemical expression of CD34 for characterization and quantification of mucosal vasculature and its probable role in malignant transformation of atrophic epithelium in oral submucous fibrosis [J]. Oral Oncol, 2010, 46(7):553-558.
[12] Sharma E, Tyagi N, Gupta V, et al. Role of angiogenesis in oral submucous fibrosis using vascular endothelial growth factor and CD34: An immunohistochemical study [J]. Indian J Dent Res, 2019, 30(5):755-762.
[13] Sun Y, Wang T, Wen QT, et al. VEGF gene transfection restores the angiogenesis of oral submucous fibrosis in mice [J]. Ann Transl Med, 2021, 9(11):930.
[14] Shen YW, Shih YH, Fuh LJ, et al. Oral submucous fibrosis: A review on biomarkers, pathogenic mechanisms, and treatments [J]. Int J Mol Sci, 2020, 21(19):7231.
[15] 唐瞻贵.口腔黏膜下纤维化回顾与展望[C]//.2019年中华口腔医学会口腔颌面外科专业委员会第十三次全国口腔颌面-头颈肿瘤内科学术会议论文汇编.2019:35-36+18.
[16] 蔡鑫嘉,姚志刚,刘桂,等.口腔黏膜下纤维化:674例临床病理研究[C]//.2019年中华口腔医学会口腔病理学专业委员会第十三次全国口腔病理学术会议论文汇编.2019:69.
[17] Bhatt P, Manjunath M, Khakhla D, et al. Assessment and correlation between functional and histological staging of oral submucous fibrosis: A clinicohistopathologic study [J]. Natl J Maxillofac Surg, 2019, 10(1):27-32.
[18] Biradar SB, Munde AD, Biradar BC, et al. Oral submucous fibrosis: A clinico-histopathological correlational study [J]. J Cancer Res Ther, 2018, 14(3):597-603.
[19] Tilakaratne WM, Ekanayaka RP, Herath M, et al. Intralesional corticosteroids as a treatment for restricted mouth opening in oral submucous fibrosis [J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2016, 122(2):224-231.
[20] Rajendran R, Rani V, Shaikh S. Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis [J]. Indian J Dent Res, 2006, 17(4):190-198.
[21] Liu J, Chen F, Wei Z, et al. Evaluating the efficacy of pentoxifylline in the treatment of oral submucous fibrosis: A meta-analysis [J]. Oral Dis, 2018, 24(5):706-716.
[22] Kumar A, Bagewadi A, Keluskar V, et al. Efficacy of lycopene in the management of oral submucous fibrosis [J]. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2007, 103(2):207-213.
[23] Gupta S, Jawanda MK, Arora V, et al. Role of lycopene in preventing oral diseases as a nonsurgical aid of treatment [J]. Int J Prev Med, 2015, 6:70.
[24] Rajesh Kashyap R, Shanker Kashyap R. Herbal derivatives in the management of mouth opening in oral submucous fibrosis-A network meta-analysis [J]. Oral Dis, 2021, 27(7):1606-1615.
[25] Borle RM, Borle SR. Management of oral submucous fibrosis: a conservative approach [J]. J Oral Maxillofac Surg, 1991, 49(8):788-791.
[26] James L, Shetty A, Rishi D, et al. Management of oral submucous fibrosis with injection of hyaluronidase and dexamethasone in grade Ⅲ oral submucous fibrosis: A retrospective study [J]. J Int Oral Health, 2015, 7(8): 82-85.
[27] 杨博,唐瞻贵.丹参联合醋酸曲安奈德注射液治疗口腔黏膜下纤维化的Meta分析[J].中成药,2018,40(10):2165-2169.
[28] 肖益彩,翦新春,郑廉,等.口腔黏膜下纤维性变病损黏膜下曲安奈德联合丹参酮液注射方法及疗效探讨[J].上海口腔医学,2017,26(2):188-192.
[29] Kalani A, Chaturvedi P. Curcumin-primed and curcumin-loaded exosomes: potential neural therapy [J]. Neural Regen Res, 2017, 12(2):205-206.
[30] Piyush P, Mahajan A, Singh K, et al. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized controlled trial [J]. Oral Dis, 2019, 25(1):73-79.
[31] Nerkar Rajbhoj A, Kulkarni TM, Shete A, et al. A comparative study to evaluate efficacy of curcumin and aloe vera gel along with oral physiotherapy in the management of oral submucous fibrosis: A randomized clinical trial [J]. Asian Pac J Cancer Prev, 2021, 22(S1):107-112.
[32] Li YH, Chang WC, Chiang TE, et al. Mouth-opening device as a treatment modality in trismus patients with head and neck cancer and oral submucous fibrosis: a prospective study [J]. Clin Oral Investig, 2019, 23(1):469-476.
[33] Gondivkar SM, Gadbail AR, Sarode SC, et al. Clinical efficacy of mouth exercising devices in oral submucous fibrosis: A systematic review [J]. J Oral Biol Craniofac Res, 2020, 10(4):315-320.
[34] Shadamarshan RA, Sharma R, Grewal R, et al. Use of the greater palatine pedicled flap for the surgical management of trismus in oral submucous fibrosis [J]. Br J Oral Maxillofac Surg, 2021, 59(8):888-893.